Inovio Biomedical Corporation To Raise Approximately $15.8 Million Through Equity Funding

SAN DIEGO--(BUSINESS WIRE)--Dec. 19, 2005--Inovio Biomedical Corporation (AMEX: INO), a late stage developer of therapies for cancer and other applications using electroporation to deliver drugs and nucleic acids, reported today that it has entered into a definitive agreement with a group of institutional investors as well as Merck & Co. Inc. (NYSE: MRK) and Vical Inc. (NASDAQ: VICL) to sell approximately $15.8 million of the Company’s common stock at $2.40 per share, which represents a premium to the closing price on December 15, 2005. In addition, the Company will issue five-year warrants to purchase 35% of the number of shares of common stock to be sold in the offering at an exercise price of approximately $2.93, a 25% premium to the closing price on December 15, 2005. Closing of the transaction is subject to approval of the terms of the offering by the American Stock Exchange.

MORE ON THIS TOPIC